利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

60 条记录 (耗时 0.037 秒)

    VEHICLE
    1.
    发明申请
    VEHICLE 有权
    车辆

    公开(公告)号：US20120259492A1

    公开(公告)日：2012-10-11

    申请号：US13439848

    申请日：2012-04-05

    申请人： Akihiro YAMAMOTO ,  Junji Kato ,  Yuichi Nakamura ,  Hiroshi Murakami

    发明人： Akihiro YAMAMOTO ,  Junji Kato ,  Yuichi Nakamura ,  Hiroshi Murakami

    IPC分类号： B60L15/00

    CPC分类号： B60K6/52 ,  B60K7/0007 ,  B60K17/02 ,  B60K17/046 ,  B60K17/356 ,  B60K2007/0046 ,  B60K2007/0061 ,  B60K2007/0092 ,  Y02T10/6265 ,  Y10S903/903

    摘要： A vehicle includes a first drive device and a second drive device. The first drive device includes a motor, a motor control device, a connection-disconnection device, and a connection-disconnection device controller. When the vehicle is driven in a state where a driving force of the first drive device is substantially zero, or the vehicle is driven only by a driving force of the second drive device, the connection-disconnection device controller couples the connection-disconnection device to establish a connected state of the connection-disconnection device. The motor control device is configured to perform loss reduction control on the motor to reduce at least one of a loss of the motor and a loss in a power transmission path in power transmitted to the first driving wheel, by establishing the connected state of the connection-disconnection device.

    摘要翻译： 车辆包括第一驱动装置和第二驱动装置。 第一驱动装置包括电动机，电动机控制装置，连接断开装置和连接断开装置控制器。 当车辆在第一驱动装置的驱动力基本上为零的状态下驱动时，或车辆仅由第二驱动装置的驱动力驱动时，连接断开装置控制器将连接断开装置连接到 建立连接断开装置的连接状态。 电动机控制装置被配置为对电动机执行减少损失控制，以通过建立连接的连接状态来减少电动机的损失和传递到第一驱动轮的动力的动力传递路径的损失中的至少一个 - 连接设备。

    Vehicle
    2.
    发明授权
    Vehicle 有权
    车辆

    公开(公告)号：US08761982B2

    公开(公告)日：2014-06-24

    申请号：US13439848

    申请日：2012-04-05

    申请人： Akihiro Yamamoto ,  Junji Kato ,  Yuichi Nakamura ,  Hiroshi Murakami

    发明人： Akihiro Yamamoto ,  Junji Kato ,  Yuichi Nakamura ,  Hiroshi Murakami

    IPC分类号： B60L9/00 ,  B60K6/52 ,  B60K7/00 ,  B60K17/356

    CPC分类号： B60K6/52 ,  B60K7/0007 ,  B60K17/02 ,  B60K17/046 ,  B60K17/356 ,  B60K2007/0046 ,  B60K2007/0061 ,  B60K2007/0092 ,  Y02T10/6265 ,  Y10S903/903

    摘要： A vehicle includes a first drive device and a second drive device. The first drive device includes a motor, a motor control device, a connection-disconnection device, and a connection-disconnection device controller. When the vehicle is driven in a state where a driving force of the first drive device is substantially zero, or the vehicle is driven only by a driving force of the second drive device, the connection-disconnection device controller couples the connection-disconnection device to establish a connected state of the connection-disconnection device. The motor control device is configured to perform loss reduction control on the motor to reduce at least one of a loss of the motor and a loss in a power transmission path in power transmitted to the first driving wheel, by establishing the connected state of the connection-disconnection device.

    摘要翻译： 车辆包括第一驱动装置和第二驱动装置。 第一驱动装置包括电动机，电动机控制装置，连接断开装置和连接断开装置控制器。 当车辆在第一驱动装置的驱动力基本上为零的状态下驱动时，或车辆仅由第二驱动装置的驱动力驱动时，连接断开装置控制器将连接断开装置连接到 建立连接断开装置的连接状态。 电动机控制装置被配置为对电动机执行减少损失控制，以通过建立连接的连接状态来减少电动机的损失和传递到第一驱动轮的动力的动力传递路径的损失中的至少一个 - 连接设备。

    Combined pharmaceutical preparation
    3.
    发明授权
    Combined pharmaceutical preparation 有权

    公开(公告)号：US09757462B2

    公开(公告)日：2017-09-12

    申请号：US13885811

    申请日：2011-10-20

    申请人： Junji Kato ,  Rishu Takimoto

    发明人： Junji Kato ,  Rishu Takimoto

    IPC分类号： A61K47/26 ,  A61K47/48

    CPC分类号： A61K47/26 ,  A61K47/549 ,  A61K47/61 ,  A61K47/6911

    摘要： The invention relates to a combined pharmaceutical composition or pharmaceutical preparation, comprising a first component containing a first ligand for a polyspecific lectin in a reticuloendothelial cell and a second component containing a carrier, a labeling agent, or a medicament for treating a disease associated with a target cell, each of which is targeted by a second ligand for a polyspecific lectin in a reticuloendothelial cell different from the first ligand, and also relates to a method for labeling a target cell and a method for treating a disease associated with a target cell, each using the same.

    Drug carrier and drug carrier kit for inhibiting fibrosis
    4.
    发明授权
    Drug carrier and drug carrier kit for inhibiting fibrosis 有权
    用于抑制纤维化的药物载体和药物载体试剂盒

    公开(公告)号：US08652526B2

    公开(公告)日：2014-02-18

    申请号：US13439330

    申请日：2012-04-04

    申请人： Yoshiro Niitsu ,  Junji Kato ,  Yasushi Sato

    发明人： Yoshiro Niitsu ,  Junji Kato ,  Yasushi Sato

    IPC分类号： A61K9/127 ,  A61K9/14 ,  A61K31/07 ,  C12N15/11 ,  A61K38/18

    CPC分类号： A61K31/07 ,  A61K9/0019 ,  A61K9/127 ,  A61K9/14 ,  A61K31/7088 ,  A61K38/1833 ,  A61K38/1841 ,  A61K38/1858 ,  A61K45/06 ,  A61K47/6911 ,  Y10S514/893 ,  Y10T428/2982 ,  A61K2300/00

    摘要： An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.

    摘要翻译： 含有类视黄醇衍生物和/或维生素A类似物作为成分的星形胶质细胞特异性药物载体; 一种使用该药物的药物递送方法; 含有该药物的药物; 以及使用该药物的治疗方法。 通过将药物载体与维生素A或维生素A类似物的类视黄醇衍生物结合或将其包封在药物载体中，用于治疗用途的药物可以特异性递送至星形胶质细胞。 结果，可以有效地有效地抑制或预防星形胶质细胞相关疾病，同时尽量减少副作用。 作为抑制星形胶质细胞活性或生长的药物，例如可以将作为胶原特异性分子伴侣的HSP47的siRNA包封在药物载体中。 因此，可以同时抑制I型至IV型胶原的分泌，从而可以有效地抑制纤维化。

    Drug Carrier and Drug Carrier Kit for Inhibiting Fibrosis
    5.
    发明申请
    Drug Carrier and Drug Carrier Kit for Inhibiting Fibrosis 有权
    用于抑制纤维化的药物载体和药物载体试剂盒

    公开(公告)号：US20080193512A1

    公开(公告)日：2008-08-14

    申请号：US11793736

    申请日：2005-12-22

    申请人： Yoshiro Niitsu ,  Junji Kato ,  Yasushi Sato

    发明人： Yoshiro Niitsu ,  Junji Kato ,  Yasushi Sato

    IPC分类号： A61K9/127 ,  A61K31/07 ,  A61P35/00

    CPC分类号： A61K31/07 ,  A61K9/0019 ,  A61K9/127 ,  A61K9/14 ,  A61K31/7088 ,  A61K38/1833 ,  A61K38/1841 ,  A61K38/1858 ,  A61K45/06 ,  A61K47/6911 ,  Y10S514/893 ,  Y10T428/2982 ,  A61K2300/00

    摘要： An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.

    摘要翻译： 含有类视黄醇衍生物和/或维生素A类似物作为成分的星形胶质细胞特异性药物载体; 一种使用该药物的药物递送方法; 含有该药物的药物; 以及使用该药物的治疗方法。 通过将药物载体与维生素A或维生素A类似物的类视黄醇衍生物结合或将其包封在药物载体中，用于治疗用途的药物可以特异性递送至星形胶质细胞。 结果，可以有效地有效地抑制或预防星形胶质细胞相关疾病，同时尽量减少副作用。 作为抑制星形胶质细胞活性或生长的药物，例如可以将作为胶原特异性分子伴侣的HSP47的siRNA包封在药物载体中。 因此，可以同时抑制I型至IV型胶原的分泌，从而可以有效地抑制纤维化。

    Authentication method and authentication system
    6.
    发明申请
    Authentication method and authentication system 审中-公开
    认证方式和认证系统

    公开(公告)号：US20070192599A1

    公开(公告)日：2007-08-16

    申请号：US11338669

    申请日：2006-01-25

    申请人： Junji Kato ,  Hirokazu Tsuruta

    发明人： Junji Kato ,  Hirokazu Tsuruta

    IPC分类号： H04L9/00

    CPC分类号： H04L9/3273 ,  H04L9/0844 ,  H04L9/16 ,  H04L2209/60 ,  H04L2209/805

    摘要： After a selection key bundle is determined by a selection key bundle determining process, the following first authentication key authenticating process is executed. An authentication processing part selects a selection encryption key from selection key bundle following a predetermined association based on a received random-number data. On the other hand, another authentication processing part selects an encryption key from the selection key bundle as a selection encryption key, following the association based on the received random-number data, encrypts the random-number data using the selection encryption key so as to acquire encrypted random-number data and transmits to the former authentication processing part. The former authentication processing part decrypts the encrypted random-number data using the selection encryption key so as to acquire decrypted random-number data and then determines whether that authentication is acceptable based on a comparison between the transmission time original random-number data and decrypted random-number data.

    摘要翻译： 在通过选择密钥束确定处理确定了选择密钥束之后，执行以下第一认证密钥认证处理。 认证处理部基于接收到的随机数数据，在预定关联之后从选择密钥束中选择选择加密密钥。 另一方面，另一认证处理部从选择密钥包中选择加密密钥作为选择加密密钥，根据接收的随机数数据进行关联，然后使用选择加密密钥加密随机数数据，从而 获取加密的随机数数据并将其发送到前一认证处理部分。 前一认证处理部分使用选择加密密钥对加密的随机数数据进行解密，以便获取解密的随机数数据，然后基于传输时间原始随机数数据和解密随机数之间的比较来确定该认证是否可接受 数字数据。

    Heat exchanger and production method for the heat exchanger
    8.
    发明申请
    Heat exchanger and production method for the heat exchanger 审中-公开
    热交换器的换热器和生产方法

    公开(公告)号：US20070062671A1

    公开(公告)日：2007-03-22

    申请号：US11522787

    申请日：2006-09-18

    申请人： Naoki Sugimoto ,  Ryouichi Sanada ,  Junji Kato

    发明人： Naoki Sugimoto ,  Ryouichi Sanada ,  Junji Kato

    IPC分类号： F28F9/00

    CPC分类号： F28F9/002 ,  F28D1/0452

    摘要： A bracket portion and a caulking pawl portion are provided on a tank cap closing an end portion of a first refrigerant header tank of an evaporator. Brazing is carried out in a state where the pawl portion is caulked and provisionally fixed to side plates by the pawl portion. As the evaporator and a radiator for electric components are coupled through the bracket portion, the coupling distance can be reduced and a suitable fastening strength between the evaporator and the radiator for electric components can be secured.

    摘要翻译： 托架部分和铆接爪部分设置在封闭蒸发器的第一制冷剂集水箱的端部的罐盖上。 在爪部被铆接并通过棘爪部临时固定在侧板上的状态下进行钎焊。 由于蒸发器和用于电气部件的散热器通过支架部分联接，所以可以减小联接距离，并且可以确保用于电气部件的蒸发器和散热器之间的合适的紧固强度。

    Drug carrier and drug carrier kit for inhibiting fibrosis
    10.
    发明授权
    Drug carrier and drug carrier kit for inhibiting fibrosis 有权

    公开(公告)号：US08591953B2

    公开(公告)日：2013-11-26

    申请号：US13439330

    申请日：2012-04-04

    申请人： Yoshiro Niitsu ,  Junji Kato ,  Yasushi Sato

    发明人： Yoshiro Niitsu ,  Junji Kato ,  Yasushi Sato

    IPC分类号： A61K9/127 ,  A61K9/14 ,  A61K31/07 ,  C12N15/11 ,  A61K38/18

    摘要： An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.